key: cord-0942987-gi9xwwte authors: Chen, Hui; Li, Zhao; Feng, Sheng; Richard-Greenblatt, Melissa; Hutson, Emily; Andrianus, Stefen; Glaser, Laurel J; Rodino, Kyle G; Qian, Jianing; Jayaraman, Dinesh; Collman, Ronald G; Glascock, Abigail; Bushman, Frederic D; Lee, Jae Seung; Cherry, Sara; Fausto, Alejandra; Weiss, Susan R; Koo, Hyun; Corby, Patricia M; Oceguera, Alfonso; O’Doherty, Una; Garfall, Alfred L; Vogl, Dan T; Stadtmauer, Edward A; Wang, Ping title: Femtomolar SARS-CoV-2 Antigen Detection Using the Microbubbling Digital Assay with Smartphone Readout Enables Antigen Burden Quantitation and Tracking date: 2021-08-12 journal: Clin Chem DOI: 10.1093/clinchem/hvab158 sha: 8147e040a8489b8d4e65165c314410509ae0b2ea doc_id: 942987 cord_uid: gi9xwwte BACKGROUND: High sensitivity SARS-CoV-2 antigen assays are desirable to mitigate false negative results. Limited data are available to quantify and track SARS-CoV-2 antigen burden in respiratory samples from different populations. METHODS: We developed the Microbubbling SARS-CoV-2 Antigen Assay (MSAA) with smartphone readout, with a limit of detection (LOD) of 0.5 pg/mL (10.6 fmol/L) nucleocapsid (N) antigen or 4000 copies/mL inactivated SARS-CoV-2 virus in nasopharyngeal (NP) swabs. We developed a computer vision and machine learning-based automatic microbubble image classifier to accurately identify positives and negatives, and quantified and tracked antigen dynamics in ICU COVID inpatients and immunocompromised COVID patients. RESULTS: Compared to qualitative RT-PCR methods, the MSAA demonstrated a positive percent agreement (PPA) of 97% (95% confidence interval (CI), 92-99%) and a negative percent agreement (NPA) of 97% (95% CI, 94-100%) in a clinical validation study with 372 residual clinical NP swabs. In immunocompetent individuals, the antigen positivity rate in swabs decreased as days-after-symptom-onset increased, despite persistent nucleic acid positivity. Antigen was detected for longer and variable periods of time in immunocompromised patients with hematologic malignancies. Total microbubble volume, a quantitative marker of antigen burden, correlated inversely with Ct values and days-after-symptom-onset. Viral sequence variations were detected in patients with long duration of high antigen burden. CONCLUSIONS: The MSAA enables sensitive and specific detection of acute infections, quantification and tracking of antigen burden, and may serve as a screening method in longitudinal studies to identify patients who are likely experiencing active rounds of ongoing replication and warrant close viral sequence monitoring. In this study, we developed and validated a highly sensitive and specific SARS-98 CoV-2 antigen assay using the microbubbling digital assay with smartphone readout 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 23 24 25 26 27 28 29 30 31 32 33 34 35 36 37 38 39 40 41 42 43 44 45 46 47 48 49 50 51 52 53 54 55 56 57 58 59 Microbubbles on the microbubbling microchips were imaged using an iPhone 11 133 or an iPad with the uHandy mobile phone microscope (9x, 5 mm focusing length, 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 23 24 25 26 27 28 29 30 31 32 33 34 35 36 37 38 39 40 41 42 43 44 45 46 47 48 49 50 51 52 53 54 55 56 57 58 59 60 134 Aidmics Biotechnology Co. A ML-based classifier was developed to classify images. In each image, we 142 counted the number of detected bubbles whose radius was above and below a set The design of MSAA is shown in Figure 1 . A monoclonal capture antibody is 154 conjugated to the surface of magnetic microbeads, and a polyclonal detection antibody 155 is biotinylated to bind to avidin coated platinum nanoparticles (PtNPs). When N protein 156 is present, immunosandwich complexes form between the magnetic microbeads and 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 23 24 25 26 27 28 29 30 31 32 33 34 35 36 37 38 39 40 41 42 43 44 45 46 47 48 49 50 51 52 53 54 55 56 57 58 59 60 179 and the 3 coronaviruses (1x10 5 pfu/mL), while an over 10 times signal increase was 180 observed for SARS-CoV-2 (1x10 5 copies/mL or 1.4x10 4 pfu/mL). We then evaluated the analytical performance of the assay in swab samples. 190 We subsequently challenged the assay with 10 rRT-PCR-negative NP swab 197 was also observed for sample 3, but not for buffer control, in the ELISA assay. This 198 indicates that the background was assay format-agnostic and intrinsic to the swab matrix. 199 Mucins have been reported as the major cause of nonspecific bindings and background 200 signals in many immunoassays using mucosal samples (21), due to their ability to bind to 201 a variety of solid surfaces (22, 23). We postulated that mucins were the source of the 239 days and >12 days after symptom onset or initial COVID diagnosis, despite positive 240 rRT-PCR results from the same samples. In the asymptomatic but rRT-PCR-positive group (n=62), the PPA was 45% (95% 242 CI, 32-58%). In this asymptomatic group, the MSAA was able to detect a pre-243 symptomatic case, in which both antigen and nucleic acid results were positive in the 244 swab sample collected one day before the patient developed cough and other 245 respiratory symptoms. Figure 3B , log-transformed total bubble volume 252 correlated inversely with Ct values, and total bubble volume decreased with days-after-253 symptom-onset. This indicates that total bubble volume is a potential quantitative 254 marker for antigen burden. We then compared two approaches (ML algorithm vs. total bubble volume Figure 3D . These results were very stable across 266 three random 50-50 splits of the full dataset (336 images) into training and testing data. 267 Overall, this demonstrates that fully automated image analysis and ML are able to 268 produce antigen burden quantitation and accurate classification from the MSAA. (Figure 4A) . To compare nucleic acid with antigen 275 dynamics, both N1 gene copy number quantified using RT-qPCR and antigen burden 276 were plotted in Figure 4A . Consistent with what was observed in Table 1 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 23 24 25 26 27 28 29 30 31 32 33 34 35 36 37 38 39 40 41 42 43 44 45 46 47 48 49 50 51 52 53 54 55 56 57 58 305 Thus, the MSAA could serve as a screen to identify patients who warrant close viral 306 sequence monitoring. We have demonstrated that the MSAA can detect the N antigen with an 309 analytical sensitivity of 0.5 pg/mL (10.6 fmol/L) and high specificity. Our observed LOD 310 is 100 times better than the stated LOD of commercially available antigen assays, and 311 comparable to the SIMOA N antigen assay (18) (Supplemental Table 4 ). The LOD in 312 swabs (4000 copies/mL) is comparable to many FDA EUA-approved rRT-PCR assays 313 (10 2 -10 5 copies/mL), better than current EUA-approved lateral flow antigen tests and the 314 majority of emerging SARS-CoV-2 antigen assays (Supplemental Table 4 ). Clinical 315 validation comparing to EUA-approved rRT-PCR methods showed excellent PPA and We have also demonstrated that total bubble volume, a quantitative output from 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 23 24 25 26 27 28 29 30 31 32 33 34 35 36 37 38 39 40 41 42 43 44 45 46 47 48 49 50 51 52 53 54 55 56 57 58 59 60 339 exception of some reports focusing on antigens in blood (16, 18, 32) and some antigen We expect that the MSAA will be able to mitigate concerns for false negatives 353 using antigen tests. However, we did not compare the MSAA with current lateral flow 354 antigen tests in a side-by-side manner. Another limitation of the study is that the data of 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 23 24 25 26 27 28 29 30 31 32 33 34 35 36 37 38 39 40 41 42 43 44 45 46 47 48 49 50 51 52 53 54 55 56 57 58 59 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 23 24 25 26 27 28 29 30 31 32 33 34 35 36 37 38 39 40 41 42 43 44 45 46 47 48 49 50 51 52 53 54 55 56 57 58 59 60 21 22 23 24 25 26 27 28 29 30 31 32 33 34 35 36 37 38 39 40 41 42 43 44 45 46 47 48 49 50 51 52 53 54 55 56 57 58 59 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 23 24 25 26 27 28 29 30 31 32 33 34 35 36 37 38 39 40 41 42 43 44 45 46 47 48 49 50 51 52 53 54 55 56 57 58 59 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 23 24 25 26 27 28 29 30 31 32 33 34 35 36 37 38 39 40 41 42 43 44 45 46 47 48 49 50 51 52 53 54 55 56 57 58 59 60 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 23 24 25 26 27 28 29 30 31 32 33 34 35 36 37 38 39 40 41 42 43 44 45 46 47 48 49 50 51 52 53 54 55 56 57 58 59 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 23 24 25 26 27 28 29 30 31 32 33 34 35 36 37 38 39 40 41 42 43 44 45 46 47 48 49 50 51 52 53 54 55 56 57 58 59 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 23 24 25 26 27 28 29 30 31 32 33 34 35 36 37 38 39 40 41 42 43 44 45 46 47 48 49 50 51 52 53 54 55 56 57 58 59 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 23 24 25 26 27 28 29 30 31 32 33 34 35 36 37 38 39 40 41 42 43 44 45 46 47 48 49 50 51 52 53 54 55 56 57 58 59 60 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 23 24 25 26 27 28 29 30 31 32 33 34 35 36 37 38 39 40 41 42 43 44 45 46 47 48 49 50 51 52 53 54 55 56 57 58 59 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 23 24 25 26 27 28 29 30 31 32 33 34 35 36 37 38 39 40 41 42 43 44 45 46 47 48 49 50 51 52 53 54 55 56 57 58 59 60 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 23 24 25 26 27 28 29 30 31 32 33 34 35 36 37 38 39 40 41 42 43 44 45 46 47 48 49 50 51 52 53 54 55 56 57 58 59 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 23 24 25 26 27 28 29 30 31 32 33 34 35 36 37 38 39 40 41 42 43 44 45 46 47 48 49 50 51 52 53 54 55 56 57 58 59 60 To eliminate the background signal, we took advantage 203 of the high molecular weight of mucins and used a filter with molecular weight cutoff 204 between mucins (200 kDa~200 MDa) and N protein (47.08 kDa) (Pierce™ protein 205 concentrator PES, 100K MWCO) to remove mucins and retain filtrate for testing We compared the analytical sensitivity of the assay for inactivated SARS-CoV-2 To determine the analytical sensitivity of the MSAA for viruses in NP swabs, 214 different amounts of inactivated SARS-CoV-2 viruses were spiked into an rRT-PCR-215 negative NP swab pool, lysed, filtered and tested using the MSAA. As shown in Figure 2C, the number of microbubbles increased linearly with the concentrations of inactivated 217 SARS-CoV-2 viruses between 0-18000 copies/mL (virus genome RNA concentration, 218 determined by reverse transcription−quantitative polymerase chain reaction To determine the LOD following the FDA antigen assay template (3), we 221 tested 10 rRT-PCR-negative NP swab pools, 21 swab pools spiked with inactivated 222 SARS-CoV-2 viruses at 2000 copies/mL and 21 pools at 4000 copies/mL Author Contributions: All authors confirmed they have contributed to the intellectual content of this 389 paper and have met the following 4 requirements: (a) significant contributions to the conception and 390 design, acquisition of data, or analysis and interpretation of data; (b) drafting or revising the article for 391 intellectual content Disclosures or Potential Conflicts of Interest: Upon manuscript submission, all authors 396 completed the author disclosure form. Disclosures and/or potential conflicts of interest: 397 398 Employment or Leadership: P. Wang Consultant or Advisory Role: D. Vogl, Karyopharm Therapeutics, GSK, Oncopeptides, Takeda, Amgen, 400 Celgene Corporation Stock Ownership: None declared Wang have received support from National Institute of Health 404 grants R01DA035868, R01EB029363 and National Science Foundation grant 1928334. S.R. Weiss has 405 received support from National Institute of Health grant R01AI40442 and Penn Center for Research on 406 Coronaviruses and Other Emerging Pathogens. We thank the RADx-Tech Program, Penn Center for 407 Precision Medicine, Penn Health-Tech and Penn Center for Innovation & Precision Dentistry for 408 providing funding for this project part of the National Nanotechnology Coordinated Infrastructure Program, which is 410 supported by the National Science Foundation grant NNCI-2025608 General Electric Therapeutics to institution Bill & Melinda 413 Gates Foundation INV-018479 NIH 3R01AI150246-01S1 Bill & Melinda Gates Foundation INV-018479, Mercatus Fast Grant. 415 Expert Testimony: None declared Role of Sponsor: The funding organizations played a direct role in the design of study, review and 420 interpretation of data, and preparation of manuscript Limits of detection of 6 427 approved rt-pcr kits for the novel sars-coronavirus-2 (sars-cov-2) Molecular and serological assays for sars-cov-2: 430 Insights from genome and clinical characteristics Sars-cov-2 reference panel comparative data The perplexing problem of persistently pcr-positive personnel Researchers tie severe immunosuppression to chronic covid-19 and virus 438 variants Virological assessment of hospitalized patients with covid-2019 Viral rna load as determined by cell culture as a management tool for discharge of 444 sars-cov-2 patients from infectious disease wards 447 Predicting infectious severe acute respiratory syndrome coronavirus 2 from diagnostic 448 samples. Clinical infectious diseases : an official publication of the Infectious Diseases 449 Society of Repeat covid-19 molecular testing: Correlation with recovery of infectious virus, 452 molecular assay cycle thresholds, and analytical sensitivity Pathogenesis and transmission of sars-cov-2 in golden hamsters Antigen-457 based testing but not real-time polymerase chain reaction correlates with severe acute 458 respiratory syndrome coronavirus 2 viral culture Evaluation of 460 rapid antigen test for detection of sars-cov-2 virus Evaluating the clinical utility and sensitivity of sars-cov-2 antigen testing in relation to rt-463 pcr ct values covid-19) update: Fda authorizes first antigen test to help in the rapid 465 detection of the virus that causes covid-19 in patients Ultrasensitive high-resolution profiling of early seroconversion in patients with covid-19 Ultra-472 sensitive serial profiling of sars-cov-2 antigens and antibodies in plasma to understand 473 disease progression in covid-19 patients with severe disease Sars-coronavirus-2 nucleocapsid protein measured in blood using a simoa ultra-sensitive 477 immunoassay differentiates covid-19 infection with high clinical sensitivity N-480 protein presents early in blood, dried blood and saliva during asymptomatic and 481 symptomatic sars-cov-2 infection Quantitation of femtomolar-level 483 protein biomarkers using a simple microbubbling digital assay and bright-field 484 smartphone imaging A computational approach to edge detection Use of the hough transformation to detect lines and curves in 488 pictures Conditioning saliva for use in a microfluidic 490 biosensor Complex desorption of mucin from silica Coronavirus disease 2019 (covid-19) emergency use authorizations for medical devices/ 496 in vitro diagnostics euas Prolonged severe acute respiratory syndrome coronavirus 2 replication in an 501 immunocompromised patient Long-term severe acute respiratory syndrome coronavirus 2 (sars-cov-2) 504 infectiousness among three immunocompromised patients: From prolonged viral 505 shedding to sars-cov-2 superinfection Shedding of viable sars-cov-2 after immunosuppressive therapy for cancer Sars-510 cov-2 evolution during treatment of chronic infection Acute immune signatures and their legacies in severe acute respiratory 513 syndrome coronavirus-2 infected cancer patients Figure 1. Schematic of the Microbubbling SARS-CoV-2 Antigen Assay NP) swab eluant is first treated with lysis buffer to release N proteins 536 from SARS-CoV-2 viruses. N protein is then detected by the smartphone-based 537 microbubbling digital assay. The microbubble images are quantified and classified as 538 positive or negative by computer vision and ML algorithms Performance of the Microbubbling SARS-CoV-2 Antigen Assay. A. Dose-541 response curve of recombinant N-protein in buffer. Mean ± 3 standard deviations Dose-response curve of inactivated SARS-CoV-2 viruses in rRT-PCR-negative NP Examples from clinical NP swab samples. B. Upper: Log transformed total 548 bubble volume correlated inversely with Ct. by Pearson linear correlation. Lower: Total 549 bubble volume decreased with days-after-symptom-onset. C Tracking antigen burden using Microbubbling SARS-CoV-2 Antigen Assay 555 in A. inpatients in ICU and B. immunocompromised patients (rRT-PCR persistently 556 positive) with either hematological malignancies or transplants